# Kathleen I. Pritchard

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/kathleen-i-pritchard/

## Facts

| Field | Value |
| --- | --- |
| Citations | 58,938 |
| Field | Breast Cancer Treatment Studies |
| h-index | 99 |
| i10-index | 302 |
| Last Known Institution | Sunnybrook Health Science Centre |
| OpenAlex ID | https://openalex.org/A5049907389 |
| ORCID iD | https://orcid.org/0000-0003-0758-9666 |
| Works | 613 |

## Researcher papers

- [Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013](https://scholariq.org/papers/personalizing-the-treatment-of-women-with-early-breast-cancer-highlights-of-the/)
- [Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.](https://scholariq.org/papers/polychemotherapy-for-early-breast-cancer-an-overview-of-the-randomised-trials/)
- [A Randomized Trial of Letrozole in Postmenopausal Women after Five Years of Tamoxifen Therapy for Early-Stage Breast Cancer](https://scholariq.org/papers/a-randomized-trial-of-letrozole-in-postmenopausal-women-after-five-years-of/)
- [Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial](https://scholariq.org/papers/prognostic-and-predictive-value-of-the-21-gene-recurrence-score-assay-in/)
- [Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials](https://scholariq.org/papers/increasing-the-dose-intensity-of-chemotherapy-by-more-frequent-administration-or/)
- [Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials](https://scholariq.org/papers/trastuzumab-for-early-stage-her2-positive-breast-cancer-a-meta-analysis-of-13/)
- [Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials](https://scholariq.org/papers/anthracycline-containing-and-taxane-containing-chemotherapy-for-early-stage/)

## Researcher topics

- [Breast Cancer Treatment Studies](https://scholariq.org/topics/breast-cancer-treatment-studies/)
- [Estrogen and related hormone effects](https://scholariq.org/topics/estrogen-and-related-hormone-effects/)
- [Cancer Treatment and Pharmacology](https://scholariq.org/topics/cancer-treatment-and-pharmacology/)
- [Advanced Breast Cancer Therapies](https://scholariq.org/topics/advanced-breast-cancer-therapies/)
- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)

## Researcher university

- [Sunnybrook Health Science Centre](https://scholariq.org/institutions/sunnybrook-health-science-centre/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.